Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 and shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act), nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act,
except as shall be expressly set forth by specific reference in
such filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 9, 2017 |
About Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Recent Trading Information
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) closed its last trading session 00.00 at 11.01 with 1,282,102 shares trading hands.